Niagen Bioscience, Inc.
$4.87
▼
-3.1%
2026-04-21 08:19:01
www.niagenbioscience.com
NCM: NAGE
Explore Niagen Bioscience, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$389.99 M
Current Price
$4.87
52W High / Low
$14.69 / $4.16
Stock P/E
22.44
Book Value
$0.96
Dividend Yield
—
ROCE
16.53%
ROE
28.35%
Face Value
—
EPS
$0.2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
117
Beta
2.23
Debt / Equity
3.68
Current Ratio
4.86
Quick Ratio
3.83
Forward P/E
14.06
Price / Sales
2.78
Enterprise Value
$299.29 M
EV / EBITDA
19.85
EV / Revenue
2.31
Rating
Strong Buy
Target Price
$13.6
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
Cons
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
| 2. | Artelo Biosciences, Inc. | $4.53 | — | $3.96 M | — | 917.46% | -16.25% | $85.8 / $2.96 | $-1.89 |
| 3. | Rhythm Pharmaceuticals, Inc. | $87.72 | — | $5.99 B | — | -51.31% | -90.45% | $122.2 / $55.31 | $2.07 |
| 4. | Genprex, Inc. | $1.16 | — | $10.45 M | — | -194.32% | -3.39% | $55 / $1.15 | $3.78 |
| 5. | Century Therapeutics, Inc. | $2.34 | — | $467.28 M | — | -5.16% | -5.98% | $3.04 / $0.43 | $1.82 |
| 6. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 7. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 33.84 M | 33.99 M | 31.12 M | 30.48 M | 29.12 M |
| Operating Profit | 2.1 M | 4.24 M | 3.19 M | 4.77 M | 7.11 M |
| Net Profit | 4.13 M | 4.58 M | 3.61 M | 5.06 M | 7.18 M |
| EPS in Rs | 0.05 | 0.06 | 0.05 | 0.06 | 0.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 129.42 M | 99.6 M | 83.57 M | 72.05 M |
| Operating Profit | 14.3 M | 7.73 M | -5.6 M | -18.63 M |
| Net Profit | 17.38 M | 8.55 M | -4.94 M | -16.54 M |
| EPS in Rs | 0.22 | 0.11 | -0.06 | -0.21 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 106.41 M | 68.28 M | 54.96 M | 54.06 M |
| Total Liabilities | 29.87 M | 22.18 M | 26.51 M | 25.39 M |
| Equity | 76.53 M | 46.09 M | 28.46 M | 28.67 M |
| Current Assets | 96.81 M | 64.1 M | 49.53 M | 46.57 M |
| Current Liabilities | 19.92 M | 17.95 M | 20.62 M | 17.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 13.5 M | 12.11 M | 7.12 M | -15.1 M |
| Investing CF | -0.29 M | -0.14 M | -0.14 M | -0.33 M |
| Financing CF | 6.92 M | 5.37 M | -0.09 M | 7.65 M |
| Free CF | 13.21 M | 11.95 M | 6.97 M | -15.43 M |
| Capex | -0.29 M | -0.16 M | -0.15 M | -0.33 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 19.18% | 15.99% | — | — |
| Earnings Growth % | 273.15% | 70.15% | — | — |
| Profit Margin % | 8.58% | -5.91% | -22.96% | — |
| Operating Margin % | 7.76% | -6.7% | -25.85% | — |
| Gross Margin % | 61.84% | 60.76% | 59.4% | — |
| EBITDA Margin % | 9.25% | -4.66% | -23.24% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.